KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Net Margin (2016 - 2025)

Boston Scientific's Net Margin history spans 17 years, with the latest figure at 12.72% for Q4 2025.

  • For Q4 2025, Net Margin rose 33.0% year-over-year to 12.72%; the TTM value through Dec 2025 reached 14.44%, up 337.0%, while the annual FY2025 figure was 14.44%, 337.0% up from the prior year.
  • Net Margin for Q4 2025 was 12.72% at Boston Scientific, down from 14.91% in the prior quarter.
  • Across five years, Net Margin topped out at 15.75% in Q2 2025 and bottomed at 2.56% in Q4 2021.
  • The 5-year median for Net Margin is 11.51% (2021), against an average of 10.0%.
  • The largest annual shift saw Net Margin skyrocketed 2017bps in 2021 before it tumbled -868bps in 2022.
  • A 5-year view of Net Margin shows it stood at 2.56% in 2021, then surged by 52bps to 3.89% in 2022, then surged by 249bps to 13.56% in 2023, then decreased by -9bps to 12.39% in 2024, then rose by 3bps to 12.72% in 2025.
  • Per Business Quant, the three most recent readings for BSX's Net Margin are 12.72% (Q4 2025), 14.91% (Q3 2025), and 15.75% (Q2 2025).